Khoury, Katia; Meisel, Jane L.; Yau, Christina; Rugo, Hope S.; Nanda, Rita; Davidian, Marie; Tsiatis, Butch; Chien, A. Jo; Wallace, Anne M.; Arora, Mili; Rozenblit, Mariya; Hershman, Dawn L.; Zimmer, Alexandra; Clark, Amy S.; Beckwith, Heather; Elias, Anthony D.; Stringer-Reasor, Erica; Boughey, Judy C.; Nangia, Chaitali; Vaklavas, Christos; Omene, Coral; Albain, Kathy S.; Kalinsky, Kevin M.; Isaacs, Claudine; Tseng, Jennifer; Torres, Evanthia T. Roussos; Thomas, Brittani; Thomas, Alexandra; Sanford, Amy; Balassanian, Ronald; Ewing, Cheryl; Yeung, Kay; Sauder, Candice; Sanft, Tara; Pusztai, Lajos; Trivedi, Meghna S.; Outhaythip, Ashton; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Beedle, Carolyn; Perlmutter, Jane; Pohlmann, Paula; Shatsky, Rebecca A.; Demichele, Angela; Yee, Douglas; van't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.

Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

NATURE MEDICINE

IF50

2024-09-144

PRE

Shatsky, Rebecca A.; Trivedi, Meghna S.; Yau, Christina; Nanda, Rita; Rugo, Hope S.; Davidian, Marie; Tsiatis, Butch; Wallace, Anne M.; Chien, A. Jo; Stringer-Reasor, Erica; Boughey, Judy C.; Omene, Coral; Rozenblit, Mariya; Kalinsky, Kevin; Elias, Anthony D.; Vaklavas, Christos; Beckwith, Heather; Williams, Nicole; Arora, Mili; Nangia, Chaitali; Torres, Evanthia T. Roussos; Thomas, Brittani; Albain, Kathy S.; Clark, Amy S.; Falkson, Carla; Hershman, Dawn L.; Isaacs, Claudine; Thomas, Alexandra; Tseng, Jennifer; Sanford, Amy; Yeung, Kay; Boles, Sarah; Chen, Yunni Yi; Huppert, Laura; Jahan, Nusrat; Parker, Catherine; Giridhar, Karthik; Howard, Frederick M.; Blackwood, M. Michele; Sanft, Tara; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Heditsian, Diane; Lestage, Barbara; Perlmutter, Jane; Pohlmann, Paula; Demichele, Angela; Yee, Douglas; van 't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial

新辅助治疗设置中达托波他马-德鲁克替康（Dato）联合 durvalumab（Durva）治疗策略的病理完全缓解（pCR）率：I-SPY 2.2 试验结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-011

PRE

Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression

CANCER RESEARCH

IF16.6

2024-07-112

PRE

A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer